EVMN Latest Press Releases

-- November 5, 2026 --

Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET Business Wire 6:30 AM

-- November 4, 2026 --

Evommune Announces $30 Million Private Placement Business Wire 5:10 PM

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals Business Wire 5:02 PM

-- October 1, 2026 --

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress Business Wire 8:00 AM

-- September 23, 2026 --

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Business Wire 4:05 PM

-- September 8, 2026 --

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis Business Wire 5:43 PM

-- August 6, 2026 --

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights Business Wire 4:05 PM

-- July 30, 2026 --

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis Business Wire 8:00 AM

-- July 7, 2026 --

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky PRNewswire 2:09 PM

-- June 30, 2026 --

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) PRNewswire 1:39 PM

-- June 29, 2026 --

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria Business Wire 8:30 AM

Market Data Delayed 15 Minutes